Blood Test Could Help Detect Cancer Earlier In People With Nonspecific Symptoms

Slashdot reader eastlight_jim writes:

Scientists from the University of Oxford have today published a study in Clinical Cancer Research which shows that they can use a technique called NMR (nuclear magnetic resonance) metabolomics analysis to identify patients with cancer. Specifically, they identify patients with cancer from within a population of generally unwell patients with non-specific symptoms like fatigue and weigh-loss — a traditionally hard-to-diagnose cohort.

The technique works because the NMR identifies small molecules called metabolites in the blood of patients and this information can then be used by machine learning to recognise patterns of metabolites specific to cancer, as well as identifying patients whose cancer has already spread.

The Guardian reports:
If validated, the test could enable cancer patients to be identified earlier, when they are more likely to respond to treatment, and help flag up who could benefit from early access to drugs designed to tackle metastatic cancer.

The test can also tell if the disease has spread.

There is currently no clear route through which someone with nonspecific symptoms that could be cancer is referred for further investigation…. “The problem we’ve had in the past is that if they do have cancer, that cancer is growing all the time, and when they come back the cancers are often quite advanced,” said Dr James Larkin, of the University of Oxford, who was involved in the research. Although it is difficult to know precisely how many individuals fall into this category, “it is likely to be tens of thousands of patients across the UK,” Larkin said.

Read more of this story at Slashdot.

Psilocybin Has No Short- Or Long-Term Detrimental Effects In Healthy People

New research from the Institute of Psychiatry, Psychology, & Neuroscience (IoPPN) at King’s College London, in partnership with COMPASS Pathways, has established that psilocybin can be safely administered at doses of either 10mg or 25mg to up to six participants simultaneously. King’s College London reports: The research, published in The Journal of Psychopharmacology, is an essential first step in demonstrating the safety and feasibility of psilocybin — a psychedelic drug isolated from the Psilocybe mushroom — for use within controlled settings alongside talking therapy as a potential treatment for a range of mental health conditions, including treatment-resistant depression (TRD) and PTSD. Current treatment options for these conditions are ineffective or partially effective for many people, resulting in a significant unmet need. Early research has indicated a potential for psilocybin therapy to treat these groups, but no trials have been undertaken at the scale needed for regulatory approval to make the therapy available.

The trial is the first of its kind to thoroughly investigate the simultaneous administration of psilocybin. 89 healthy participants with no recent (within 1 year) use of psilocybin were recruited. 60 individuals were randomly picked to receive either a 10mg or 25mg dose of psilocybin in a controlled environment. In addition, all participants were provided with one-to-one support from trained psychotherapists. The remaining 29 participants acted as the control group and received a placebo, also with psychological support. Participants were closely monitored for six to eight hours following administration of psilocybin and then followed up for 12 weeks. During this time, they were assessed for a number of possible changes, including sustained attention, memory, and planning, as well as their ability to process emotions. Throughout the study, there were no instances of anyone withdrawing from the study due to an adverse event, and no consistent trends to suggest that either of the psilocybin doses had any short- or long-term detrimental effects on participants.

Read more of this story at Slashdot.

Can an Athlete’s Blood Enhance Brainpower?

fahrbot-bot shares a report from The New York Times: What if something in the blood of an athlete could boost the brainpower of someone who doesn’t or can’t exercise? Could a protein that gets amplified when people exercise help stave off symptoms of Alzheimer’s and other memory disorders? That’s the tantalizing prospect raised by a new study in which researchers injected sedentary mice with blood from mice that ran for miles on exercise wheels, and found that the sedentary mice then did better on tests of learning and memory. The study, published Wednesday in the journal Nature, also found that the type of brain inflammation involved in Alzheimer’s and other neurological disorders was reduced in sedentary mice after they received their athletic counterparts’ blood. Scientific results with mice don’t necessarily translate to humans. Still, experts said the study supports a growing body of research.

The study involved mice that were about three months old — roughly the equivalent of 25-to-30-year olds for humans. Some of the mice, nocturnal animals that love to run, could freely use exercise wheels in their cages and logged about four to six miles on the wheels each night. The wheels were locked for other mice that could scoot around their cages but could not get an extended cardio workout. […] After 28 days, the researchers took a third group of mice that also did not exercise and injected them with blood plasma, the liquid that surrounds blood cells, from either the runner mice or the non-runner mice. Mice receiving runner blood did better on two tests of learning and memory than those receiving blood from the non-runner mice. In one test, which measures how long a mouse will freeze in fear when it is returned to a cage where it previously received an electric foot shock, mice with runner blood froze 25 percent longer, indicating they had better memory of the stressful event […]. In the other test, mice with runner blood were twice as fast at finding a platform submerged in opaque water, he said. The team also found that the brains of mice with runner blood produced more of several types of brain cells, including those that generate new neurons in the hippocampus, a region involved in memory and spatial learning. A genetic analysis showed that about 1,950 genes had changed in response to the infusion of runner blood, becoming either more or less activated. Most of the 250 genes with the greatest activation changes were involved in inflammation and their changes suggested that brain inflammation was reduced.

Read more of this story at Slashdot.

Suicide Pods Now Legal In Switzerland, Providing Users With a Painless Death

Switzerland is giving the green light to so-called “suicide capsules” — 3-D printed pods that allow people to choose the place where they want to die an assisted death. Global News reports: The country’s medical review board announced the legalization of the Sarco Suicide Pods this week. They can be operated by the user from the inside. Dr. Philip Nitschke, the developer of the pods and founder of Exit International, a pro-euthanasia group, told SwissInfo.ch the machines can be “towed anywhere for the death” and one of the most positive features of the capsules is that they can be transported to an “idyllic outdoor setting.”

Currently, assisted suicide in Switzerland means swallowing a capsule filled with a cocktail of controlled substances that puts the person into a deep coma before they die. But Sarco pods — short for sarcophagus — allow a person to control their death inside the pod by quickly reducing internal oxygen levels. The person intending to end their life is required to answer a set of pre-recorded questions, then press a button that floods the interior with nitrogen. The oxygen level inside is quickly reduced from 21 per cent to one per cent. After death, the pod can be used as a coffin. […]

Nitschke said his method of death is painless, and the person will feel a little bit disoriented and/or euphoric before they lose consciousness. He said there are only two capsule prototypes in existence, but a third machine is being printed now, and he expects this method to become available to the Swiss public next year.

Read more of this story at Slashdot.

Booster Shots Create a 23X Increase in Protective Antibody Levels, Study Suggests

The Los Angeles Times summarizes the results of a new medical study conducted by Northwestern University researchers on antibody levels protecting against Covid-19 in 974 people. “Those who were immunized against COVID-19 with two doses of an mRNA vaccine and received a booster shot about eight months later saw their levels of neutralizing antibodies skyrocket.

“Among this group of 33 fully vaccinated and boosted people, the median level of these antibodies was 23 times higher one week after the booster shot than it had been just before the tune-up dose.”

What’s more, their median post-booster antibody level was three times higher than was typical for another group of people whose antibodies were measured a few weeks after getting their second dose of vaccine, when they’re close to their peak.

And it was 53 times higher than that of a group of 76 unvaccinated people who had recovered from COVID-19 just two to six weeks earlier. Even compared to a group of 73 people who had weathered a bout with COVID-19 and went on to get two doses of an mRNA vaccine, the boosted group’s median antibody level was 68% higher.

Study leader Alexis Demonbreun, a cell biologist at Northwestern University’s Feinberg School of Medicine, said the data demonstrate that no matter how well protected a vaccinated person may think she is, getting a booster shot is likely to increase her neutralizing antibodies — and with it, her immunity — considerably. And because scientists expect large antibody responses to create more durable immunity, the protection afforded by the booster should last longer than the initial two-shot regimen did…

Among their other findings: After receiving two doses of vaccine, people who’d already had an asymptomatic infection were typically no better protected than vaccinated people who had never been infected.

Read more of this story at Slashdot.